Where's the harm? Drug trials play down dangers with vague language
It sounds promising when a published study on a pancreatic cancer drug concludes that the therapy has a “manageable and mostly reversible safety profile”.
But a closer look at harms data for the agent, liposomal irinotecan, published in the Lancet in 2016, reveals that five patients in the experimental arm died from drug toxicities, compared with none in the control arm.
How do these facts fit with the description of adverse events being “manageable and mostly reversible” given reincarnation